Blood test could tell doctors if breast cancer treatment will fail
NCT ID NCT06388122
Summary
This study is testing a blood test called DiviTum®TKa to see if it can predict early whether standard hormone-based treatments for advanced breast cancer will stop working. Researchers will measure a specific marker in the blood of 100 patients with hormone-positive, HER2-negative metastatic breast cancer who are receiving approved therapies. The goal is to help doctors identify treatment resistance sooner so they can adjust care more quickly.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.